Prognostic gene signature for AML

  • Zejuan Li (Contributor)
  • Tobias Herold (Contributor)
  • Chunjiang He (Contributor)
  • Ping Chen (Contributor)
  • Vindi Jurinovic (Contributor)
  • Ulrich Mansmann (Contributor)
  • Miao Sun (Contributor)
  • Xinan Yang (Contributor)
  • Hao Huang (Contributor)
  • Xi Jiang (Contributor)
  • Wolfgang Hiddemann (Contributor)
  • Abdel Elkahloun (Contributor)
  • Yanming Zhang (Contributor)
  • Michelle M. Le Beau (Contributor)
  • Lars Bullinger (Contributor)
  • Ruud Delwel (Contributor)
  • Guido Marcucci (Contributor)
  • Bob Löwenberg (Contributor)
  • Jianjun Chen (Contributor)

Dataset

Description

Acute myeloid leukemia (AML) is a heterogeneous disease in respect of molecular aberrations and prognosis. We used gene expression profiling of 562 patients treated in the German AMLCG 1999 trial to develop a gene signature that predicts survival in AML. Analysis of 562 samples (140 HGU-133plus2; 422 HGU-133A; 422 HGU-133B) from adult patients with acute myeloid leukemia (AML).
Date made available2013
PublisherArrayExpress

Access Dataset

Cite this